How to Glatiramer acetate?

Method of delaying the onset of clinically definite multiple sclerosis,Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

2 results about "Glatiramer acetate" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone) is an immunomodulator medication currently used to treat multiple sclerosis. Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.

Method of delaying the onset of clinically definite multiple sclerosis

InactiveUS20090149541A1Slow onsetOrganic active ingredientsBiocideDrugGlatiramer acetate

A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.

Method of delaying the onset of clinically definite multiple sclerosis

View all

Owner:YEDA RES & DEV CO LTD

Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

InactiveUS20110230413A1Nervous disorderAntipyreticAutoimmune conditionAutoimmune disease

A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10 / IL-18 ratio and IL-10 / IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo- / non-responder.

Owner:TEVA PHARMA IND LTD

2 results about "Glatiramer acetate" patented technology

Method of delaying the onset of clinically definite multiple sclerosis

Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

Popular searches